UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 


 

FORM 8-K

 


 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): April 27, 2011

 


 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware

 

000-30319

 

94-3265960

(State or Other Jurisdiction of
Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

(a)           The Annual Meeting of Stockholders of Theravance, Inc. was held on April 27, 2011.

 

(b)           The nominees listed below were elected directors with the respective votes set forth opposite their names:

 

 

 

Votes for

 

Votes withheld

 

Rick E Winningham

 

69,933,385

 

2,607,155

 

Jeffrey M. Drazan

 

70,048,547

 

2,491,993

 

Henrietta Holsman Fore

 

70,827,772

 

1,712,768

 

Robert V. Gunderson, Jr.

 

69,593,678

 

2,946,862

 

Arnold J. Levine. Ph.D

 

70,271,418

 

2,269,122

 

Burton G. Malkiel, Ph.D.

 

69,506,003

 

3,034,537

 

Peter S. Ringrose, Ph.D.

 

71,667,912

 

872,628

 

William H. Waltrip

 

70,131,896

 

2,408,644

 

George M. Whitesides, Ph.D

 

69,914,329

 

2,626,211

 

William D. Young

 

70,323,341

 

2,217,199

 

 

The stockholders also approved an amendment to the Company’s 2004 Employee Stock Purchase Plan increasing the aggregate number of shares of common stock authorized for issuance thereunder by 550,000 shares. The voting results are set forth below:

 

For

 

Against

 

Abstain

 

72,265,420

 

207,677

 

67,443

 

 

The voting results on a non-binding advisory vote to approve the compensation of the Company’s named executive officers disclosed in the Company’s 2011 proxy statement are set forth below:

 

For

 

Against

 

Abstain

 

71,534,583

 

919,780

 

86,177

 

 

2



 

The voting results on a non-binding advisory vote on the frequency of the advisory vote on executive compensation are set forth below:

 

One Year

 

Two Years

 

Three Years

 

Abstain

 

67,482,840

 

120,481

 

4,869,596

 

67,623

 

 

In light of these results, the Board of Directors has determined to hold an annual advisory vote on executive compensation.

 

The stockholders also ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011. The voting results are set forth below:

 

For

 

Against

 

Abstain

 

77,579,400

 

362,526

 

7,107

 

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

THERAVANCE, INC.

 

 

 

 

Dated:  May 2, 2011

By:

/s/ Rick E Winningham

 

 

 

 

 

Rick E Winningham

 

 

Chief Executive Officer

 

4